Two routes to a GLP-1 medicine in the United States are usually described as if they were the same kind of purchase. One is a manufacturer's own channel, LillyDirect, which sells Zepbound to self-paying patients at a published price per strength. The other is a telehealth platform, Hims, which bills a recurring membership and then bills the medicine separately. On the prices we could verify on 24 September 2026, a modelled twelve months of branded Wegovy bought through a membership platform came to about $5,566, against about $3,888 for the identical pens bought direct from the manufacturer's own pharmacy. The difference is close to the membership fee and almost nothing else. This article sets out the arithmetic, names the source and date behind every figure, and is blunt about the part of the comparison we could not verify, which is larger than we would like.
DoseTruth is a price-comparison publisher: it is not a pharmacy, not a telehealth provider, and it does not prescribe or dispense any medication. This article is general information about published prices, published regulatory documents and published research, it is not medical advice, and decisions about any medicine or any dose belong with a licensed clinician. Every price below carries the date it was checked and the source it came from. Prices in this market move often, so confirm the live figure on the day you pay.
What does a year on LillyDirect actually cost?
On the Zepbound savings page we read on 24 September 2026, the self-pay programme prices the single-patient-use KwikPen at $299 a month for 2.5 mg, $399 a month for 5 mg, and $449 a month for 7.5 mg, 10 mg, 12.5 mg and 15 mg. The same page states the terms in plain words. The offer is for self-paying patients only, reimbursement from insurance or a healthcare account is not allowed, the buyer must be a resident of the United States or Puerto Rico and at least eighteen, and the card expires on 31 December 2026.
Two conditions do most of the work in a yearly total. The first is the refill window. To hold the $449 price at 7.5 mg and above, the page states the buyer must complete the refill purchase within 45 days of the delivery or received date of the previous fill. We have worked that rule through in detail in the LillyDirect 45 day rule in real numbers. The second condition is the one almost nobody models, and we cover it in its own section below.
| Strength | Self-pay price per month | Condition attached | Source tier |
|---|---|---|---|
| 2.5 mg KwikPen | $299 | Self-pay only, no insurance reimbursement | Manufacturer's own page |
| 5 mg KwikPen | $399 | Self-pay only | Manufacturer's own page |
| 7.5 mg to 15 mg KwikPen | $449 | Refill within 45 days of previous delivery | Manufacturer's own page |
| Any strength, offer lapsed | Reported as $599 to $1,049 | Outside the 45 day window or past 11 fills | Commercial aggregators only, not primary |
The final row deserves its warning label. We found the out-of-window prices of $599 at 7.5 mg, $699 at 10 mg, $849 at 12.5 mg and $1,049 at 15 mg only on commercial comparison sites, not on any page Lilly publishes that we were able to open on 24 September 2026. Those four numbers are therefore not primary and we do not lean on them in any total below.
Why is the LillyDirect year eleven fills and not twelve?
The savings page states that the card may be used for a maximum of up to 11 prescription fills per calendar year, and on re-reading the page specifically to separate the commercial insurance card from the self-pay programme, that 11-fill cap applies to the self-pay KwikPen route as well. This matters more than the headline price. A person who fills every month will exhaust the offer in November and meet an unsubsidised December. A year on the LillyDirect self-pay card is eleven discounted fills, not twelve.
So the honest LillyDirect total is a total for eleven fills, and we present it that way. A person stepping up through the strengths and settling at 7.5 mg or above pays $299 for the first fill, $399 for the second and $449 for the remaining nine, which is $4,739. A person who settles at 5 mg pays $299 plus ten fills at $399, which is $4,289. These are our calculations from the published unit prices, not prices quoted by Lilly, and a real titration schedule is a clinical matter we are not modelling.
What does a year on Hims actually cost?
Hims bills in two streams that run on separate schedules. The membership is one charge and the medicine is another, and cancelling one does not cancel the other. The most recent reputable secondary source we were able to open, a Healthline review dated 25 June 2026, states the membership is $39 for the first month and then $149 a month, and states explicitly that this does not include the cost of GLP-1 medications, which it puts in a range of $149 to $1,899 a month. Twelve months of that membership is $39 plus eleven payments of $149, which is $1,678 before a single dose is dispensed.
The medicine price is where our evidence thins out badly, and we will not dress that up. We attempted to read the Hims and Hers published price pages directly on 24 September 2026 and every one of them returned an HTTP 403 response to our fetcher, including the weight loss landing page, the frequently asked questions page and the product pages on the Hers domain. Every Hims price in this article is therefore secondary, and none of it comes from a page Hims published that we were able to open ourselves.
What we can anchor is the ceiling. Novo Nordisk and Hims and Hers announced on 9 March 2026, in a press release filed as an exhibit to a Form 8-K, that Ozempic at 0.5 mg, 1 mg and 2 mg and Wegovy injections at 1.7 mg and 2.4 mg and Wegovy tablets at 1.5 mg, 4 mg, 9 mg and 25 mg would come to the Hims platform. Reporting of that agreement states Hims would offer the branded medicines at the same cash prices as Novo's other telehealth partners. Neither the filed press release nor the reporting we read named a dollar figure. Neither company published a price for the product at the centre of their own settlement.
That leaves the manufacturer's own pharmacy as the best available proxy for the medicine leg. On the Wegovy cost page and the NovoCare savings page, both read on 24 September 2026, the self-pay ladder is $199 a month for the first two fills at 0.25 mg or 0.5 mg as a limited-time offer running to 31 December 2026, then $349 a month for the standard pen strengths and $399 a month for the 7.2 mg high-dose pen. The tablets run $149 a month at 1.5 mg, $199 at 4 mg and $299 at 9 mg and 25 mg. We traced that tablet step in the oral Wegovy price rise from 149 to 199.
What happens when you put the two years side by side?
The comparison only becomes fair once the membership is shown as its own line rather than buried in a bundled monthly figure. Table 2 models twelve months at the verified unit prices. The arithmetic is ours and we invite anyone to check it.
| Route | Membership over the year | Medicine over the year | Modelled total | How the medicine figure is built |
|---|---|---|---|---|
| LillyDirect, Zepbound KwikPen, settles at 7.5 mg or above | None | $4,739 | $4,739 | $299 plus $399 plus nine fills at $449, capped at 11 fills |
| LillyDirect, Zepbound KwikPen, settles at 5 mg | None | $4,289 | $4,289 | $299 plus ten fills at $399, capped at 11 fills |
| NovoCare Pharmacy direct, Wegovy pen | None | $3,888 | $3,888 | Two fills at $199 then ten at $349 |
| Hims, Wegovy pen at telehealth parity | $1,678 | $3,888 | $5,566 | Same ladder, plus $39 then eleven months at $149 |
| Hims, Wegovy tablets at telehealth parity | $1,678 | $3,338 | $5,016 | $149 plus $199 plus ten fills at $299, plus membership |
The fourth row against the third row is the finding. Same molecule, same manufacturer, same pens, same published ladder, and a difference of $1,678 across the year. The membership is the entire difference, so the gap between these two routes is not a medicine, it is a subscription. Whether that subscription is worth $1,678 is a judgement about clinical support, messaging access and convenience, and it is not a judgement we are equipped to make for anyone. It is, however, a number that should be visible before someone signs up rather than discovered in month seven.
Two cautions on the Hims rows. The parity assumption is exactly that, an assumption, built from a settlement description rather than a price list. Secondary sources also disagree with each other about what Hims charges. One telehealth guide dated April 2026 puts injectable Wegovy at $299 a month, oral Wegovy at $249 and Zepbound at $399, while the Healthline review dated June 2026 lists Zepbound vials and KwikPen from $299 and a Zepbound injection at $1,899. We could not reconcile those, and we are not going to pretend a range that wide is a price. The pattern where a bundled monthly figure hides a separate recurring charge is the same one we documented in how Noom bills by the quarter and not the month, and the general problem of an intermediary charging more than the direct channel is the subject of why GoodRx costs more than buying Wegovy direct.
Are the two routes even selling the same thing?
No, and this is the most common error in comparisons of this kind. LillyDirect's self-pay programme sells tirzepatide as Zepbound. The Hims route described in the March 2026 settlement sells semaglutide as Wegovy or Ozempic. These are different molecules with different published trial results, so a cheaper annual total on one route is not the same product bought for less.
The head-to-head evidence exists and it is good. SURMOUNT-5 randomised 751 adults across 32 sites in the United States and Puerto Rico between April 2023 and November 2024, comparing tirzepatide at a maximum tolerated dose of 10 mg or 15 mg weekly against semaglutide at a maximum tolerated dose of 1.7 mg or 2.4 mg weekly. The primary endpoint was percent change in body weight at 72 weeks. The result was a 20.2 per cent reduction on tirzepatide against 13.7 per cent on semaglutide, reported at p less than 0.001, published as Aronne LJ, Horn DB, le Roux CW, and others, in the New England Journal of Medicine in 2025, volume 393, issue 1, pages 26 to 36.
Now the caveats we are obliged to state. We read that citation and those figures through the American College of Cardiology's journal scan, because the New England Journal of Medicine page and the PubMed record both refused our fetcher on 24 September 2026, so this is a professional society reporting a peer-reviewed trial rather than the trial paper itself. The trial is described in secondary summaries as open label, which we were unable to confirm at the journal. It was funded by the manufacturer of one of the two drugs compared. It measured maximum tolerated doses under trial conditions, which is not what an average buyer experiences. The trial compared two molecules, it did not compare two retailers, and it says nothing whatsoever about which channel anyone should buy from.
What happened to the cheap compounded option?
It closed, through a sequence of dated regulatory steps that are worth stating precisely because a great deal of stale pricing advice still assumes otherwise. The FDA determined the tirzepatide shortage resolved on 19 December 2024, and its enforcement discretion for state-licensed 503A pharmacies ended on 18 February 2025 with 503B outsourcing facilities following on 19 March 2025. The agency determined the semaglutide shortage resolved on 21 February 2025, with 503A discretion ending 22 April 2025 and 503B discretion ending 22 May 2025. On 30 April 2026 the FDA went further and proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk substances, with a comment period running to 29 June 2026.
| Date | Step | Effect |
|---|---|---|
| 19 December 2024 | FDA declares tirzepatide shortage resolved | Starts the wind-down clock for compounders |
| 21 February 2025 | FDA declares semaglutide shortage resolved | Same clock, different molecule |
| 22 April and 22 May 2025 | Semaglutide 503A then 503B discretion ends | Copies of the approved drug no longer tolerated |
| 9 March 2026 | Novo Nordisk dismisses its Hims patent case, partnership announced | Hims stops advertising compounded GLP-1s |
| 30 April 2026 | FDA proposes 503B bulks list exclusion | Would close bulk compounding by rule, not discretion |
Hims did not exit compounding entirely. Its own Form 10-Q for the quarter ended 31 March 2026 states the company evolved its United States weight loss offering to match its global approach of providing access to branded GLP-1 medications, while offering access to compounded GLP-1 medications through the platform on a limited scale. Reporting of the settlement records that compounded products remain available where a provider determines one is clinically necessary. Compounded semaglutide is no longer the cheap default it was in 2024, and any annual cost model built on 2024 compounded pricing is now wrong by a large margin.
Does Medicare change the comparison?
For those eligible, it changes it completely, and it makes both commercial routes look expensive. The Medicare GLP-1 Bridge runs from 1 July 2026 to 31 December 2027 and sets a $50 monthly copay for eligible beneficiaries. Novo's own Wegovy cost page, read on 24 September 2026, states that eligible Medicare patients pay just $50 a month for the Wegovy pen and pill across all dose strengths. A KFF analysis published 11 May 2026 adds the detail that the negotiated price behind it is $245 per 30-day supply, that the included drugs are all formulations of Foundayo and Wegovy plus the KwikPen formulation of Zepbound, that eligibility requires provider attestation and one of three clinical categories, and that the $50 copay does not count towards the Part D deductible or the $2,100 out-of-pocket maximum.
Twelve months at $50 is $600, against our modelled $4,739 on LillyDirect self-pay and $5,566 on a membership route. Eligibility is the whole question and it is narrow, but for anyone inside it, no cash-pay comparison is the relevant one. The wider reset of these programmes is covered in the GLP-1 price routes that reset on 31 December 2026.
How strong is each claim in this article?
This is the table we would want to read first if someone else had written this piece. We have marked our own weakest evidence rather than waiting for a reader to find it.
| Claim | Type of evidence | Strength | Why |
|---|---|---|---|
| LillyDirect self-pay ladder is $299, $399, $449 | Manufacturer's own published page, read twice today | Strong | Primary seller page for its own price, terms quoted on the page |
| The self-pay card caps at 11 fills per calendar year | Terms and conditions on the same page, re-read to separate the two offers | Strong | Verified against the specific risk that it applied only to the insurance card |
| NovoCare self-pay ladder is $199 then $349, tablets $149 to $299 | Two manufacturer pages, read today | Strong | Corroborated across the Wegovy cost page and the NovoCare offer page |
| FDA shortage and enforcement dates | FDA statements and press announcement | Strong | Government primary source with explicit dates |
| Novo and Hims settled on 9 March 2026 on these terms | Press release filed as an 8-K exhibit, plus the company's own 10-Q | Strong | Regulatory filings, corroborated by two trade outlets |
| Medicare Bridge $50 copay, 1 July 2026 to 31 December 2027 | Manufacturer page plus KFF policy analysis | Moderate to strong | Two independent sources agree, but we did not open the CMS document itself |
| Tirzepatide 20.2 per cent against semaglutide 13.7 per cent at 72 weeks | Peer-reviewed trial, read via a professional society summary | Moderate | Journal and PubMed both refused our fetcher, funder made one of the drugs |
| Hims membership is $39 then $149 a month | Secondary health publisher dated 25 June 2026 | Weak | Hims own pages returned 403, no primary confirmation obtained |
| Hims sells branded Wegovy at NovoCare parity prices | Inference from settlement descriptions, no price published | Weak | An assumption, and secondary sources contradict each other on Hims prices |
| Out-of-window Zepbound prices of $599 to $1,049 | Commercial aggregator sites only | Very weak | Not primary, not used in any total in this article |
Read that table honestly and the headline comparison is asymmetric. The LillyDirect side of this article rests on a page we opened and quoted, and the Hims side rests on sources Hims did not write. That asymmetry exists because one company publishes its prices in a form a reader can check and the other blocked every attempt we made to read its own price pages on 24 September 2026. We are reporting the blockage rather than quietly routing around it, because it is itself the most useful thing we learned today.
What should change in how you read either offer?
Three habits survive contact with this dataset. Separate the recurring platform charge from the medicine charge before comparing anything, because a bundled monthly figure is not a price, it is a package. Count fills rather than months, because an eleven-fill cap and a 45-day refill window both convert a tidy annual figure into a messier one. Check the expiry date on every offer, because the Lilly card, the Novo introductory pen price and the Novo pricing page all point at the same cliff edge. 31 December 2026 is the single largest uncertainty in every cash-pay row above.
We should also mark where this article is weaker than our usual work. Our method treats the advertised entry price and the steady-state price as two different numbers, and we set that method out in how we measure the gap between advertised price and maintenance dose, with the introductory-offer version worked through in what $25 for the first month actually costs over a year. Applying that method here produced a clean result on the manufacturer side and a frankly provisional one on the platform side. Our strongest number in this piece is one we calculated from published unit prices, not one either company told us. A price checked today is not a price guaranteed tomorrow, and the cheaper route on paper is not automatically the right route for any individual.
Frequently asked questions
Is LillyDirect always cheaper than Hims?
On the modelled twelve months in Table 2, the LillyDirect self-pay route came to $4,739 against $5,566 for a membership route carrying branded Wegovy, using prices checked on 24 September 2026. That is not a general rule. The two routes sell different molecules, the Hims figures are secondary, and eligibility for insurance or the Medicare Bridge changes the ordering entirely.
Does LillyDirect charge a membership fee?
We found no membership or subscription fee on the Zepbound self-pay terms we read on 24 September 2026. A prescription is still required, and obtaining one through an independent telehealth provider may carry its own separate fee that varies by provider. We were unable to open LillyDirect's own pages on 24 September 2026 to verify any such fee, so we are not quoting a figure for it.
Why is the LillyDirect year capped at eleven fills?
The savings page states the card may be used for a maximum of up to 11 prescription fills per calendar year, and on a targeted re-read we confirmed that limit applies to the self-pay KwikPen programme and not only to the commercial insurance card. A twelfth fill inside the same calendar year would fall outside the offer.
Can I still get compounded semaglutide more cheaply?
The regulatory position has changed substantially. FDA enforcement discretion for compounding semaglutide ended on 22 April 2025 for 503A pharmacies and 22 May 2025 for 503B outsourcing facilities, and on 30 April 2026 the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. Hims states it offers compounded GLP-1s only on a limited scale where a provider determines one is clinically necessary. Any question about whether a compounded product is appropriate is a clinical one for a licensed prescriber.
Why could you not verify the Hims prices directly?
Every Hims and Hers price page we attempted on 24 September 2026 returned an HTTP 403 response to our fetcher, including the weight loss landing page, the frequently asked questions page and the Hers product pages. We therefore relied on a Healthline review dated 25 June 2026 for the membership structure and on the Novo settlement documents for the medicine, and we have rated both rows weak in Table 4.
Which figures here are our own arithmetic rather than quoted prices?
Every total in Table 2 is our calculation from published unit prices, and no company quoted any of those annual figures. The unit prices behind the LillyDirect and NovoCare rows are primary and quoted. The unit prices behind the two Hims rows combine a secondary membership figure with an assumed parity price for the medicine.
Sources
- Zepbound savings and self-pay terms, Eli Lilly, read 24 September 2026, for the $299, $399 and $449 ladder, the 45 day refill window, the 11 fill annual cap and the 31 December 2026 expiry.
- What to pay for Wegovy, Novo Nordisk, read 24 September 2026, for the self-pay ladder and the Medicare Bridge $50 copay.
- NovoCare Wegovy savings offer, read 24 September 2026, corroborating the $199 introductory price, the $349 standard price and the tablet ladder.
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, for the shortage resolution and enforcement discretion dates.
- FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, 30 April 2026.
- Hims and Hers press release filed as an 8-K exhibit, 9 March 2026, for the Novo Nordisk collaboration terms and product list.
- Hims and Hers Form 10-Q for the quarter ended 31 March 2026, for the statement on compounded GLP-1 access at limited scale.
- STAT News on the Novo Nordisk and Hims settlement, 9 March 2026.
- BioPharma Dive on the Novo and Hims agreement, for the price parity description.
- American College of Cardiology journal scan of SURMOUNT-5, citing Aronne LJ, Horn DB, le Roux CW, and others, New England Journal of Medicine 2025, volume 393, issue 1, pages 26 to 36.
- KFF on the BALANCE model and the Medicare GLP-1 Bridge, published 11 May 2026.
- Healthline review of Hims weight loss, dated 25 June 2026, the source for the $39 first month and $149 monthly membership. This is a secondary health publisher and not a primary Hims page.
- Pharmaceutical Executive on the LillyDirect self-pay programme, 16 June 2025, recording the earlier $349 and $499 ladder that the December 2025 reduction replaced. This is trade press, not a primary source.